
Browsing restrictions can be lifted for a fee.
Center Laboratories, Inc. engages in the manufacture and trading of various medicines in Taiwan. It engages in the research and development of small molecule drugs; manufacture and sale of pharmaceuticals; development of proteins and antibodies; and pharmaceutical CDMO, medical device, nutritional health and agribiotechnology, stem cell and immune cell therapy, and industry investment fund and venture capital businesses. The company was founded in 1959 and is headquartered in Taipei, Taiwan.
4123
晟德
-0.22%
(-0.00)
The most recent financial report for 晟德 (4123) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4123's short-term business performance and financial health. For the latest updates on 4123's earnings releases, visit this page regularly.
According to historical valuation range analysis, 晟德 (4123)'s current price-to-earnings (P/E) ratio is 9.87, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 晟德 (4123) reported an Operating Profit of 13.22M with an Operating Margin of 3.68% this period, representing a decline of 79.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 晟德 (4123) announced revenue of 359.11M, with a Year-Over-Year growth rate of -8.5%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 晟德 (4123) held Total Cash and Cash Equivalents of 521.51M, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 晟德 (4123) achieved the “three margins increasing” benchmark, with a gross margin of 40.01%%, operating margin of 3.68%%, and net margin of 756.76%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4123's profit trajectory and future growth potential.
According to the past four quarterly reports, 晟德 (4123)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.8. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
晟德 (4123)'s Free Cash Flow (FCF) for the period is 1.66B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 50.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.